Multi-Epitope-Based Peptide Vaccine Against Bovine Parainfluenza Virus Type 3: Design and Immunoinformatics Approach

Area of Science:

• Veterinary immunology
• Vaccine development
• Computational biology

Background:

• Bovine parainfluenza virus type 3 (BPIV3) causes significant economic losses in cattle due to bovine respiratory disease complex (BRDC).
• Limited commercial vaccine options exist for BPIV3, highlighting the need for new vaccine strategies.
• Fusion (F) and hemagglutinin-neuraminidase (HN) proteins are key BPIV3 antigens for eliciting neutralizing antibodies.

Purpose of the Study:

• To design and computationally evaluate a novel multi-epitope-based peptide vaccine (MEBPV) for BPIV3 using immunoinformatics.
• To assess the vaccine's physicochemical properties, immunological potential, and binding affinity to immune receptors.
• To establish a foundation for developing safe and effective BPIV3 subunit vaccines.

Main Methods:

• Immunoinformatics was used to select high-antigenicity, low-toxicity, and low-allergenicity epitopes from BPIV3 F and HN proteins.
• Epitopes were combined with linkers and adjuvants, and the resulting MEBPV's properties were evaluated computationally.
• Molecular docking, molecular dynamics simulations, and immune simulations were performed to predict binding affinity and immune responses.
• The vaccine sequence was cloned into a pET-28a (+) vector for potential expression in Escherichia coli.

Main Results:

• The designed MEBPV demonstrated favorable physicochemical and immunological attributes through computational analysis.
• Molecular simulations indicated strong binding affinity and stability with TLR4 receptors, and potential binding with TLR2 and TLR3.
• Immune simulations predicted robust humoral and cellular immune responses, including elevated interferon-γ (IFN-γ) production.
• The vaccine sequence was successfully cloned into an expression vector.

Conclusions:

• The in silico approach successfully designed a promising MEBPV candidate for BPIV3.
• The predicted strong immunogenicity and receptor binding suggest potential protective efficacy against BPIV3.
• Further in vitro and in vivo studies are warranted to validate the vaccine's safety and efficacy in cattle.
• This study offers a novel strategy for developing subunit vaccines against BPIV3 and other viral infections.